Lupin Appoints FMCG Veteran Anand Kripalu as Independent Director

Written By :  sheeba farhat
Published On 2026-02-14 15:11 GMT   |   Update On 2026-02-14 15:11 GMT
Advertisement

Mumbai: Global pharma major Lupin Limited (Lupin) has announced the appointment of Anand Kripalu as an Independent Director. Anand Kripalu brings over three decades of leadership experience in the fast-moving consumer goods(FMCG) sector.

He currently serves as Executive Director of EPL Limited and previously served as its Managing Director and Global CEO until December 31, 2025. Prior to EPL, Anand held several distinguished leadership roles, including Managing Director and CEO at Diageo India and President – India and South-East Asia at Mondelez International (Cadbury). Earlier in his career, he spent more than 20 years at Unilever, where he held roles across senior general management, sales, and marketing across geographies.

Advertisement

Anand graduated from IIT Madras with a B.Tech in Electronics and earned an MBA from IIM Calcutta. He is a recipient of the Distinguished Alumnus Award from both schools and has also completed the Advanced Management Program at Wharton Business School. He currently serves as an Independent Director on the boards of Swiggy Limited and United Breweries Limited, having previously served as a director at Marico Limited.

Manju D Gupta, Chairman, Lupin said, “We are delighted to welcome Anand to the Board. His vast experience will be invaluable in advancing Lupin’s strategic priorities and reinforcing our position in the global pharmaceutical industry.”

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News